Glenmark Pharma gets US FDA nod to expand RYALTRIS nasal spray for children 6‑11 years

What Glenmark announced

Glenmark Pharmaceuticals Limited filed a press‑release with the NSE and BSE on 21 July 2026 stating that the United States Food and Drug Administration (US FDA) has granted approval to expand the indication of RYALTRIS® nasal spray for the treatment of Seasonal Allergic Rhinitis (SAR) in children aged 6 to less than 12 years. The approval adds a younger pediatric cohort to the product’s existing US label, which already covered adults and patients 12 years and older.

The company highlighted that the decision was supported by a Phase 3, randomized, double‑blind, placebo‑controlled trial that enrolled 446 children aged 6‑11 years. Over a 14‑day treatment period, RYALTRIS® demonstrated statistically significant improvement in nasal symptoms compared with placebo and was well tolerated.

Details of the FDA approval

• Product: RYALTRIS® nasal spray (olopatadine hydrochloride + mometasone furoate) – 665 µg/25 µg per spray.
• New indication: Treatment of SAR symptoms in pediatric patients 6 years ≤ age < 12 years.
• Study evidence: Phase 3 trial, 446 participants, double‑blind, placebo‑controlled, 14‑day duration; showed efficacy and safety.
• Regulatory status: With this approval, RYALTRIS® is now FDA‑cleared for all ages 6 years and above in the United States.
• Commercialisation: Effective 1 April 2026, Glenmark Pharmaceuticals Inc., USA took over end‑to‑end commercialisation, brand strategy, market access, distribution and customer engagement for RYALTRIS® in the US.

Expansion of Glenmark’s respiratory portfolio

The company positioned the approval as a milestone that strengthens its innovative respiratory franchise. RYALTRIS® was originally approved by the FDA in 2022 for adults and patients 12 years and older. Since then, the product has secured approvals across the European Union, United Kingdom, Australia, South Korea, Russia and China. In FY 26, Glenmark launched RYALTRIS® in 11 additional markets, bringing the total number of countries with the product to 56.

Key facts at a glance

Why this matters for investors

The FDA’s expanded approval widens the addressable market for RYALTRIS® in the United States, a region that already represents a significant share of Glenmark’s respiratory revenues. By moving to direct commercialisation, Glenmark gains full control over pricing, distribution and promotional activities, potentially improving margins compared with a third‑party licensing model. The Phase 3 data provide regulatory confidence and may facilitate future label extensions or new product launches within the same combination‑therapy platform. While the filing does not disclose projected sales or revenue uplift, the broader indication and direct market presence are likely to be factored into the company’s medium‑term growth outlook for its US specialty portfolio.

Conclusion

Glenmark Pharmaceuticals has secured US FDA approval to extend RYALTRIS® nasal spray to children aged 6‑11 years, backed by a robust Phase 3 trial. The company now directly commercialises the product in the United States, reinforcing its strategic shift toward greater ownership of its respiratory brands. The announcement does not contain quantitative financial guidance, and the impact on Glenmark’s earnings will depend on market uptake and pricing decisions in the coming quarters.